Table 2.
HIV disease markers stratified by antiretroviral treatment status among participants with perinatal HIV infection.
| Characteristic | APHIV with | P value | |
|---|---|---|---|
| Early ART initiation | Delayed ART initiation | ||
| Number | 45 | 21 | |
| Age at ART initiation (years) | 2.4 (0.9, 3.4) | 7.2 (6.7, 8.2) | < 0.001 |
| Overall ART duration (years) | 12.8 (11.3, 13.8) | 8.1 (7.8, 9.7) | < 0.001 |
| Cumulative NRTI exposure (years) | 12.8 (11.3, 13.8) | 8.1 (7.8, 9.7) | < 0.001 |
| Cumulative PI exposure (years) | 5.1 (0.0, 10.3) | 0.1 (0.0, 4.9) | 0.015 |
| Cumulative NNRTI exposure (years) | 7.0 (3.4, 10.6) | 6.4 (3.7, 8.1) | 0.49 |
| Cumulative INSTRI exposure (years)a | 0 | 0 | 0.92 |
| Current ART regimen | |||
| 2 different NRTIs + 1 NNRTI | 21 (47%) | 11 (52%) | 0.74 |
| 2 different NRTIs + 1 PI | 23 (51%) | 10 (48%) | |
| Otherb | 1 (2%) | 0 (0%) | |
| Undetectable HIV RNA viral loadc | 28 (64%) | 12 (60%) | 0.78 |
| Current CD4+ cell count (cells/mL) | 753 (558, 928) | 592 (402, 795) | 0.011 |
| < 350 | 5 (12%) | 3 (14%) | 0.76 |
| Nadir CD4+ cell count, (cells/mL) | 574 (422, 835) | 457 (368, 720) | 0.025 |
| < 350 | 7 (16%) | 5 (24%) | 0.44 |
| History of AIDS-related illness | 12 (29%) | 4 (21%) | 0.54 |
Values are reported as median (25th, 75th percentile) or number (%).
PI protease inhibitors, NNRTI nonnucleoside reverse transcriptase inhibitors, NRTI nucleoside reverse transcriptase inhibitors, INSTI integrase strand transfer inhibitor.
aOnly one participant exposed to an integrase strand transfer inhibitor for total duration of 1.7 years.
bParticipant receiving 1 NRTI + 1 PI + 1 INSTI.
cDetection limit ≥ 40 viral copies/mL.